The UK-based sequencing technology firm continues to seek invalidation of PacBio's patents, despite unsuccessful earlier efforts.
The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.
In Nature this week: circular consensus sequencing method to sequence and assemble a human genome, a new CRISPR platform using the Cpf1 endonuclease, and more.
The firm reported total revenues of $24.6 million, with $21.3 million in product revenue, and expects its acquisition by Illumina to be completed in Q4 2019.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The patent, EP3170904, "Compositions and methods for nucleic acid sequencing," is the second PacBio patent revoked by the EPO this year.
As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.
Flye and wtdbg2, both released this year, work with Pacific Biosciences and Oxford Nanopore data and can assemble bacterial and more complex genomes.
The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
The Competition and Markets Authority is in charge of promoting competition and reducing anti-competitive activities in the UK.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.